SGLT-2 inhibitors for patients with heart failure: What have we learned recently?

Authors

Mahmoud Al Rifai, Baylor College of Medicine, United States
L. Kristin Newby, Duke University School of Medicine, United States
Ajith P. Nair, Baylor College of Medicine, United States
Arunima Misra, Baylor College of Medicine, United States
Joseph G. Rogers, Texas Heart Institute, United States
Savitri Fedson, Baylor College of Medicine, United States
Salim S. Virani, Baylor College of Medicine, United StatesFollow

Document Type

Article

Department

Office of the Provost; Cardiology

Abstract

Purpose of review: In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent findings: Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms. SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Current atherosclerosis reports

Recommended Citation

Rifai, M. A., Newby, L. K., Nair, A. P., Misra, A., Rogers, J. G., Fedson, S., Virani, S. S. (2022). SGLT-2 inhibitors for patients with heart failure: What have we learned recently?. Current atherosclerosis reports, 24(8), 627-634.
Available at: https://ecommons.aku.edu/provost_office/112